BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, Bai Y, Bian J, Zhang L, Yang X, Wang A, Xie F, Shi W, Yang H, Pan J, Hu K, Guan M, Zhao L, Huo L, Mao Y, Sang X, Wang K, Zhao H. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 2020;9:414-24. [PMID: 32832493 DOI: 10.21037/hbsn-20-338] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 26.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang XB, Zhang LH, Xue JN, Wang YC, Yang X, Zhang N, Liu D, Wang YY, Xun ZY, Li YR, Sun HS, Zhao LJ, Zhao HT. High incidence combination of multiple primary malignant tumors of the digestive system. World J Gastroenterol 2022; 28(41): 5982-5992 [DOI: 10.3748/wjg.v28.i41.5982] [Reference Citation Analysis]
2 Zhao J, Guo Y, Ding W, Han G, Jiang C, Yang C, Hu Y, Zhang L, Wu C, Ni M, Kong X, Huang T, Zhang C, Xia Y. Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study. Front Oncol 2022;12:965711. [DOI: 10.3389/fonc.2022.965711] [Reference Citation Analysis]
3 Tam VC, Ramjeesingh R, Burkes R, Yoshida EM, Doucette S, Lim HJ. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective. Current Oncology 2022;29:7072-7085. [DOI: 10.3390/curroncol29100555] [Reference Citation Analysis]
4 Harding JJ, Khalil DN, Fabris L, Abou-Alfa GK. Rational development of combination therapies for biliary tract cancers. J Hepatol 2022:S0168-8278(22)03078-1. [PMID: 36150578 DOI: 10.1016/j.jhep.2022.09.004] [Reference Citation Analysis]
5 Zhang T, Zhang C, Fu Z, Gao Q. Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. Pharmaceutics 2022;14:1768. [DOI: 10.3390/pharmaceutics14091768] [Reference Citation Analysis]
6 Xie P, Guo L, Zhang B, Xu Y, Song Q, Shi H, Ye Q, Li H, Xiao Y. Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review. Front Oncol 2022;12:911202. [DOI: 10.3389/fonc.2022.911202] [Reference Citation Analysis]
7 Zuo B, Yang X, Yang X, Bian J, Long J, Wang D, Ning C, Wang Y, Xun Z, Wang Y, Lu X, Mao Y, Sang X, Zhao H. A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. Cancer Immunol Immunother 2022;71:1889-1896. [DOI: 10.1007/s00262-021-03121-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Shi C, Li Y, Yang C, Qiao L, Tang L, Zheng Y, Chen X, Qian Y, Yang J, Wu D, Xie F. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China. Front Immunol 2022;13:946861. [DOI: 10.3389/fimmu.2022.946861] [Reference Citation Analysis]
9 Ding X, Li G, Sun W, Shen Y, Teng Y, Xu Y, Li W, Liu M, Chen J. Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study. Front Oncol 2022;12:907055. [DOI: 10.3389/fonc.2022.907055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen R, Zheng D, Li Q, Xu S, Ye C, Jiang Q, Yan F, Jia Y, Zhang X, Ruan J. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215853] [Reference Citation Analysis]
11 Xie L, Huang J, Wang L, Ren W, Tian H, Hu A, Liang J, Jiao Y, Li Y, Zhou Q, Zhang W. Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma. Front Pharmacol 2022;13:894407. [PMID: 35721133 DOI: 10.3389/fphar.2022.894407] [Reference Citation Analysis]
12 Jiang Q, Huang J, Zhang B, Li X, Chen X, Cui B, Li S, Guo G. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:801909. [PMID: 35309350 DOI: 10.3389/fimmu.2022.801909] [Reference Citation Analysis]
13 Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H, Chen C, Wang W, Shen L, Zhou A. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology 2022. [PMID: 35491432 DOI: 10.1002/hep.32548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Giorgione R, Risaliti M, Bartolini I, Rossi G, Pillozzi S, Muiesan P, Taddei A, Antonuzzo L. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers. Immunotherapy 2022. [PMID: 35382560 DOI: 10.2217/imt-2021-0257] [Reference Citation Analysis]
15 Cowzer D, Harding JJ. Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. Cancers 2022;14:1800. [DOI: 10.3390/cancers14071800] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Gray S, Lamarca A, Edeline J, Klümpen H, Hubner RA, Mcnamara MG, Valle JW. Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers 2022;14:1789. [DOI: 10.3390/cancers14071789] [Reference Citation Analysis]
17 Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, Ruan J, Chen J. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Front Oncol 2022;12:809709. [PMID: 35280760 DOI: 10.3389/fonc.2022.809709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang Y, Yang X, Wang D, Yang X, Wang Y, Long J, Zhou J, Lu Z, Mao Y, Sang X, Guan M, Zhao H. Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Front Oncol 2022;12:785535. [DOI: 10.3389/fonc.2022.785535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Salloum A, Habre M, Chebl JA, Chebl KA, Atallah C, Medawar G, Kourie HR. Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. Immunotherapy 2022. [PMID: 35232283 DOI: 10.2217/imt-2021-0244] [Reference Citation Analysis]
20 Yuan J, Xu L, Zhou J, Shen L. Application of immune checkpoint inhibitors in hepatobiliary cancers. iLIVER 2022;1:43-48. [DOI: 10.1016/j.iliver.2022.03.002] [Reference Citation Analysis]
21 Long J, Wang D, Wang A, Chen P, Lin Y, Bian J, Yang X, Zheng M, Zhang H, Zheng Y, Sang X, Zhao H. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Med 2022;14:20. [PMID: 35197093 DOI: 10.1186/s13073-022-01024-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
22 Oliviero B, Varchetta S, Mele D, Pessino G, Maiello R, Falleni M, Tosi D, Donadon M, Soldani C, Franceschini B, Torzilli G, Piccolo G, Barabino M, Opocher E, Maestri M, Bernuzzi S, Wucherpfennig KW, Mondelli MU, Mantovani S. MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma. OncoImmunology 2022;11:2035919. [DOI: 10.1080/2162402x.2022.2035919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Zhu S, Bian L, Lv J, Liu B, Shen J. A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors. Front Immunol 2021;12:788629. [PMID: 35003107 DOI: 10.3389/fimmu.2021.788629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Qiu Z, Ji J, Xu Y, Zhu Y, Gao C, Wang G, Li C, Zhang Y, Zhao J, Wang C, Wen X, Zhang Z, Li B, Zhang Z, Cai S, Li B, Jiang X. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes. BMC Med 2022;20:64. [PMID: 35130881 DOI: 10.1186/s12916-021-02197-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhu S, Liu C, Dong Y, Shao J, Liu B, Shen J. A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. Front Oncol 2021;11:788635. [PMID: 34976828 DOI: 10.3389/fonc.2021.788635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zhang Q, Liu X, Wei S, Zhang L, Tian Y, Gao Z, Jin M, Yan S. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Front Oncol 2021;11:751391. [PMID: 34900698 DOI: 10.3389/fonc.2021.751391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
27 Lee TY, Bates SE, Abou-Alfa GK. Equipoise, drug development, and biliary cancer. Cancer 2021. [PMID: 34817855 DOI: 10.1002/cncr.34020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent Intrahepatic Cholangiocarcinoma - Review. Front Oncol 2021;11:776863. [PMID: 34746017 DOI: 10.3389/fonc.2021.776863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Lu Y, Jin J, Du Q, Hu M, Wei Y, Wang M, Li H, Li Q. Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. Front Cell Dev Biol 2021;9:730240. [PMID: 34568339 DOI: 10.3389/fcell.2021.730240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Toward personalized therapy for cholangiocarcinoma: new insights and challenges. Expert Rev Gastroenterol Hepatol 2021;15:1241-3. [PMID: 34553646 DOI: 10.1080/17474124.2021.1984879] [Reference Citation Analysis]
32 Hack SP, Zhu AX. Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:1007-15. [PMID: 34459336 DOI: 10.1080/13543784.2021.1974838] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lu M, Zhang X, Gao X, Sun S, Wei X, Hu X, Huang C, Xu H, Wang B, Zhang W, Li Z, Feng X, Zheng J, Zhang Q. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. Pharmacol Res 2021;:105829. [PMID: 34411731 DOI: 10.1016/j.phrs.2021.105829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Xu J, Bai Y, Sun H, Bai C, Jia R, Li Y, Zhang W, Liu L, Huang C, Guan M, Zhou J, Su W. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer 2021. [PMID: 34355801 DOI: 10.1002/cncr.33803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
36 Huang P, Zhou Y, Chen Y. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. J Gastrointest Cancer 2021. [PMID: 34312770 DOI: 10.1007/s12029-021-00637-7] [Reference Citation Analysis]
37 Hewitt DB, Rahnemai-Azar AA, Pawlik TM. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opin Investig Drugs 2021;30:827-35. [PMID: 34102935 DOI: 10.1080/13543784.2021.1940948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Yao W, Gong W. Immunotherapy in cholangiocarcinoma: From concept to clinical trials. Surgery in Practice and Science 2021;5:100028. [DOI: 10.1016/j.sipas.2021.100028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
39 Yang X, Hu Y, Yang K, Wang D, Lin J, Long J, Xie F, Mao J, Bian J, Guan M, Pan J, Huo L, Hu K, Yang X, Mao Y, Sang X, Zhang J, Wang X, Zhang H, Zhao H. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer 2021;9:e001942. [PMID: 33972389 DOI: 10.1136/jitc-2020-001942] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
40 Neureiter D, Mayr C, Kiesslich T. The challenges of combinatory immunotherapy for biliary tract cancer. Expert Opin Investig Drugs 2021;30:591-4. [PMID: 33874822 DOI: 10.1080/13543784.2021.1916467] [Reference Citation Analysis]
41 Wang D, Yang X, Long J, Lin J, Mao J, Xie F, Wang Y, Wang Y, Xun Z, Bai Y, Yang X, Guan M, Pan J, Seery S, Sang X, Zhao H. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. Front Oncol 2021;11:646979. [PMID: 33912461 DOI: 10.3389/fonc.2021.646979] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
42 Zhang T, Merle P, Wang H, Zhao H, Kudo M. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 2021;10:180-92. [PMID: 33898559 DOI: 10.21037/hbsn-2021-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 17.0] [Reference Citation Analysis]
43 Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
44 Deng Z, Xiao M, Du D, Luo N, Liu D, Liu T, Lian D, Peng J. DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer. Onco Targets Ther 2021;14:2003-17. [PMID: 33776450 DOI: 10.2147/OTT.S294332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
45 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 55.0] [Reference Citation Analysis]
46 Ueno M. Immunotherapy for Pancreatic Cancer and Cholangiocarcinoma. Management of Pancreatic Cancer and Cholangiocarcinoma 2021. [DOI: 10.1007/978-981-16-2870-2_15] [Reference Citation Analysis]
47 Lu M, Zhang X, Gao X, Sun S, Wei X, Hu X, Huang C, Wang B, Zhang W, Xu H, Li Z, Feng X, Zheng J, Zhang Q. Lenvatinib Enhances T Cell Immunity and the Efficacy of Adoptive Chimeric Antigen Receptor-Modified T Cells by Decreasing Myeloid-Derived Suppressor Cells  in Cancer. SSRN Journal. [DOI: 10.2139/ssrn.3779886] [Reference Citation Analysis]
48 Vogel A, Bathon M, Saborowski A. Immunotherapies in clinical development for biliary tract cancer. Expert Opin Investig Drugs 2021;30:351-63. [PMID: 33382361 DOI: 10.1080/13543784.2021.1868437] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
49 Mo DC, Luo PH, Huang SX, Wang HL, Huang JF. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. Int Immunopharmacol 2021;91:107281. [PMID: 33338862 DOI: 10.1016/j.intimp.2020.107281] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
50 Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.Cancers (Basel). 2020;12. [PMID: 32722188 DOI: 10.3390/cancers12082039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]